Abstract Body

HIV-1 persisting in a latent form in resting CD4+ T cells despite effective antiretroviral therapy is the major barrier to cure. A promising therapeutic approach known as ‘shock and kill’ seeks to achieve cure by sequentially reversing latency in infected cells and then promoting the killing of productively infected cells. To date, however, no single LRA has been shown to reduce latent reservoir size in infected individuals. Functional genetic screening, especially CRISPR/Cas9-based screening, provides a global unbiased approach to understand the molecular aspects of HIV-1 infection. However, few studies focused on systematically identifying LRA combinations that overcome the limitations of individual LRAs.

We established a polyclonal in vitro model for HIV-1 latency. HIV-1 gene expression can be re-induced in >90% of this population by TNF-? treatment as evidenced by GFP expression. To identify candidate drug targets that potentially synergize with existing LRAs, we performed genome-wide CRISPR screening followed by induction of HIV-1 gene expression in latently infected cells using a suboptimal dose of a selected LRA, and then sorted for GFP+ cells directly. A gene whose knockout leads to enhanced GFP expression may emerge as the candidate drug target for synergy with the stimulating LRA if inhibitors of its function exist.

We tested this approach using the SMAC mimetic AZD5582, an inhibitor of the non-canonical NF-kappa b (ncNF-?B) pathway, as an LRA and identified HDAC2, a histone deacetylation complex blocked by some HDAC inhibitors and BRD2, part of the Bromodomain and Extra-Terminal motif (BET) protein family that are targeted by BET inhibitors. Using CD4+ T cells from individuals on antiretroviral therapy, we confirmed synergy between AZD5582 and several HDAC inhibitors and between AZD5582 and the BET inhibitor JQ1. Remarkably, a reciprocal screen using an HDAC inhibitor as an LRA identified ncNF-kb regulators, especially BIRC2, as a druggable synergistic candidate for use in combination with HDAC inhibition, confirming the validity of this approach.

Our studies provide novel insights into the roles of host factors in HIV-1 reactivation and validate a system for finding drug combinations for HIV-1 latency reversal.